The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers

NCT ID: NCT00820703

Last Updated: 2010-08-31

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2009-12-31

Brief Summary

Diabetic foot ulcers are sores on the feet that occur in 15% of diabetic patients some time during their lifetime. Once an ulcer develops, the risk of lower-extremity amputation is increased 8-fold in people with diabetes. New treatments that improve the number of ulcers that heal and/or speed up healing are urgently needed. Initial studies with a new drug called Nexagon® (developed by CoDa Therapeutics, Inc.) support the concept that healing of diabetic foot ulcers can be improved with topical application of Nexagon®. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to diabetic foot ulcers at various doses. A proposed randomized controlled trial will randomly allocate (e.g., by the toss of a coin) 24 people with diabetic foot ulcers to Nexagon® (one of three different doses) or vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed over four weeks to monitor their response to the treatment, specifically with regards to the amount of healing that occurs.

Conditions

Diabetic Foot Ulcer

Keywords

Nexagon; CoDa; ulcer; diabetic; foot

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Nexagon®

Intervention Type: DRUG

Nexagon® vehicle

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female aged 18 and older

2. Female subjects must be a) post-menopausal, b) surgically sterilized, c) practicing abstinence, or d) using hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study

3. Diabetes mellitus (type I or II) with an HbA1c < 10.0%

4. Diagnosis of neuropathic foot ulcer

5. Cutaneous, full thickness (University of Texas grade A1), below ankle surface ulcer between 0.5 and 5.0 cm2 post-debridement

6. A viable, granulating wound

7. Ulcer present for > 4 weeks prior to study entry

8. An ankle brachial index between 0.70 and 1.3 measured during screening or within three months prior to the Day -14 visit

9. Signed informed consent form

Exclusion Criteria

1. Decrease or increase in the ulcer size by 30% or more during a14 day "run-in" period

2. Cannot tolerate the off-loading method or comply with standard-of-care

3. An ulcer which shows signs of clinical infection

4. The ulcer to be treated requires operative debridement.

5. An ulcer positive for β-hemolytic streptococcus upon culture.

6. Requirement for total contact casts

7. The ulcer has more than 50% slough, significant necrotic tissue, osteomyelitis, bone, tendon, or capsule exposure

8. Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer)

9. Congestive heart failure NYHA class II - IV

10. Coronary heart disease with STEMI, CABG, or PTCA within the last 6 months

11. Active osteomyelitis of the study foot

12. Active connective tissue disease

13. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination

14. Treatment with systemic corticosteroids (

15. Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation

16. Pregnancy or lactation

17. eGFR < 25 mL/min

18. Poor nutritional status defined as an albumin < 25 g/L

19. Significant peripheral edema

20. Known prior inability to complete required study visits during study participation

21. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance

22. Use of a platelet-derived growth factor within the 28 days prior to screening

23. Use of any investigational drug or therapy within the 28 days prior to screening

24. Any other factor which may, in the opinion of the Investigator, compromise participation and follow-up in this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OcuNexus Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

CoDa Therapeutics

Locations

Middlemore Hospital

Auckland, Auckland, New Zealand

Countries

New Zealand

Other Identifiers

NEX-ULC-003

Identifier Type: -

Identifier Source: org_study_id